Skip to main content
. 2013 Jan;83(1):106–121. doi: 10.1124/mol.112.081802

Fig. 5.

Fig. 5.

Selective modulation of GluK2/GluK5 by group I mGlu activation. Whole-cell currents were recorded from oocytes 3 days after injection with GluK2/GluK5, GluK2/GluK5/mGlu1, and GluK2/GluK5/mGlu5 mRNAs. AMPA steady-state currents from GluK2/GluK5/mGlu1 and GluK2/GluK5/mGlu5 were significantly potentiated after application of DHPG (n ≥ 4, *P < 0.05, ****P < 0.001; one-way ANOVA with Bonferroni’s post-tests). DHPG had a minuscule effect on GluK2/GluK5 in the absence of either group I mGlu receptor (n = 6). CHPG (a selective mGlu5 agonist) produced a similar potentiation of GluK2/GluK5/mGlu5 as DHPG (n = 4). Bath application of the group II mGlu agonist DCG IV had no effect.